Welcome to our dedicated page for Ingevity SEC filings (Ticker: NGVT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Ingevity Corporation (NYSE: NGVT) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures, along with AI-powered context to help interpret them. Ingevity is a specialty materials and chemical manufacturer organized into three segments—Performance Materials, Advanced Polymer Technologies and Performance Chemicals—and its filings document how these businesses are managed, restructured and financed over time.
Investors can use Ingevity’s Form 10-K annual reports and Form 10-Q quarterly reports to review segment information, including sales and EBITDA for Performance Materials (activated carbon), Advanced Polymer Technologies (caprolactone polymers) and Performance Chemicals (specialty chemicals and pavement or road technologies). These reports also describe the applications for Ingevity’s products, such as adhesives, agrochemicals, asphalt paving, certified biodegradable bioplastics, coatings, elastomers, pavement markings, lubricants, oil drilling and automotive components.
Ingevity’s Form 8-K current reports are particularly important for tracking material events that affect NGVT stock. Recent 8-K filings detail the asset purchase agreement and subsequent amendment with Mainstream Pine Products, LLC for the sale of the North Charleston crude tall oil refinery and the majority of the Industrial Specialties product line, the classification of those operations as discontinued, and the completion of the transaction. Other 8-Ks describe leadership transitions in finance and business segments, the completion of a portfolio review and the decision to explore strategic alternatives for the Advanced Polymer Technologies segment and the Performance Chemicals Road Markings business, as well as preliminary earnings announcements.
On this page, AI-generated summaries highlight the key points of each filing, helping users quickly understand what a lengthy 8-K, 10-Q or 10-K means for Ingevity’s portfolio, margins, cash flow and capital allocation. Filings related to stock repurchases, strategic divestitures and executive changes are surfaced so that investors can monitor how the company is reshaping its specialty chemicals and materials portfolio. Users can also review exhibits referenced in 8-Ks, such as asset purchase agreements and recast financial information, to gain deeper insight into the structure and impact of major transactions.
Ingevity Corp senior executive Richard Allen White Jr. reported several tax-related share dispositions of common stock. On March 2, 2026, shares were withheld by the company at $71.64 per share to cover tax withholding obligations tied to restricted stock units that vested in 2023, 2024, and 2025. These were tax-withholding transactions, not open market sales, and White continues to hold a meaningful direct ownership stake after the withholdings.
Ingevity Corp executive vice president and chief financial officer Mary Dean Hall reported tax-related share dispositions on common stock. On March 2, 2026, she surrendered a total of 4,148 shares at $71.64 per share to satisfy withholding taxes on vesting RSU awards from 2023, 2024, and 2025. These are coded as “F” transactions, meaning shares were withheld by the company to cover tax obligations rather than sold in open-market trades. After these transactions, she directly holds 37,427 shares of Ingevity common stock.
Ingevity Corp senior vice president and chief HR officer Terrance M. Dyer reported equity compensation and a related tax withholding transaction. He received a grant of 3,621 shares of common stock at $0.00 per share, tied to restricted stock units that vest in three equal installments on February 27, 2027, 2028, and 2029. To cover tax withholding on 2025 RSUs that vested, 550 shares were disposed at $71.64 per share. After these transactions, he directly holds 7,698 common shares.
Ingevity Corp senior executive receives equity award. SVP and President, APT, Michael N. Shukov acquired 1,389 shares of Ingevity common stock on a grant basis, with no cash paid per share. The award is in the form of restricted stock units under the Ingevity Corporation 2025 Omnibus Incentive Plan.
The units will vest in three equal installments on February 27, 2027, February 27, 2028, and February 27, 2029, aligning the executive’s compensation with longer-term company performance through time-based vesting.
Castillo Ruth reported acquisition or exercise transactions in this Form 4 filing.
Ingevity Corp senior executive Ruth Castillo, SVP and President of Performance Materials, reported receiving a grant of 3,688 shares of common stock as a stock award. These restricted stock units were granted at no cash cost and will vest in three equal installments on February 27, 2027, 2028, and 2029.
Li David H reported acquisition or exercise transactions in this Form 4 filing.
Ingevity Corp President & CEO David H. Li reported an equity award of 38,179 shares of common stock. The filing labels this as a grant or award, with a price of $0.0000 per share, indicating it is a stock-based compensation grant rather than an open-market purchase.
According to the footnotes, the award consists of restricted stock units granted under the Ingevity Corporation 2025 Omnibus Incentive Plan and scheduled to vest in three equal installments on February 27, 2027, 2028, and 2029. After this grant, Li’s directly held common stock position is reported as 156,890 shares, which includes earlier purchases of 364 and 162 shares through the company’s employee stock purchase plan.
Ingevity Corp EVP and CFO Mary Dean Hall reported equity award activity involving company common stock. On February 26, 2026, she acquired 1,780 shares through the settlement of performance-based restricted stock units after the Talent and Compensation Committee certified that performance goals were met. On the same date, 873 shares were withheld by the company to cover tax obligations related to these vested awards. Following these transactions, she directly owned 41,775 shares of Ingevity common stock.
Ingevity Corp senior executive Richard Allen White Jr., SVP and President of Performance Chemicals, reported stock-based compensation awards of common stock. On February 26, 2026, he acquired 1,204 shares at $0 per share and 430 shares at $70.52 per share as grant or award transactions. Footnotes explain that performance-based restricted stock units were certified and settled in common shares rather than cash.
Ingevity Corp senior vice president Phillip John Platt reported equity compensation activity involving company common stock. On February 26, 2026, he acquired 247 shares at no cost through a grant tied to performance-based restricted stock units that were settled in shares. On the same date, 108 shares at $70.52 per share were withheld by the company to cover tax obligations related to these vested performance share units. Following these transactions, his directly held common stock balance reported in the filing was 28,911 shares.
Ingevity Corp senior vice president and general counsel Ryan C. Fisher reported equity compensation activity involving company common stock. On February 26, 2026, he acquired 192 shares at a stated price of $0.00 per share from the vesting and settlement of performance-based restricted stock units. On the same date, the company withheld 94 shares at a price of $70.52 per share to cover tax obligations related to this vesting. After these transactions, Fisher directly owned 15,393 shares of Ingevity common stock.